Alterity Therapeutics Files 6-K, Incorporates into Registration Statements
Ticker: PRNAF · Form: 6-K · Filed: Mar 15, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration-statement, administrative
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K, incorporating it into existing S-8 and F-3 filings. Nothing new, just housekeeping.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on March 15, 2024, to incorporate by reference into several of its existing Registration Statements on Form S-8 and Form F-3. The filing includes a Notice of Extraordinary General Meeting as Exhibit 99.1.
Why It Matters
This filing serves to update and integrate information into existing SEC filings, which is crucial for maintaining compliance and transparency for investors holding or considering securities covered by those registration statements.
Risk Assessment
Risk Level: low — This filing is primarily administrative, incorporating previous information into existing registration statements, and does not introduce new material risks.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Filer of the 6-K
- Form S-8 (document) — Registration statement type incorporated by reference
- Form F-3 (document) — Registration statement type incorporated by reference
- March 2024 (date) — Reporting period for the Form 6-K
- March 15, 2024 (date) — Filing date of the Form 6-K
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information to the SEC and to be incorporated by reference into Alterity Therapeutics Limited's existing Registration Statements on Form S-8 and Form F-3.
What exhibits are included with this Form 6-K?
The Form 6-K includes Exhibit 99.1, which is a Notice of Extraordinary General Meeting.
Which registration statements are being updated by this filing?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates that it files annual reports under Form 20-F.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-03-14 19:01:41
Filing Documents
- ea0201773-6k_alterity.htm (6-K) — 14KB
- ea020177301ex99-1_alterity.htm (EX-99.1) — 93KB
- ex99-1_001.jpg (GRAPHIC) — 23KB
- ex99-1_002.jpg (GRAPHIC) — 2KB
- ex99-1_003.jpg (GRAPHIC) — 775KB
- ex99-1_004.jpg (GRAPHIC) — 515KB
- 0001213900-24-022723.txt ( ) — 1920KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notice of Extraordinary General Meeting 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: March 14 , 2024 2